• Assay Search

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
      • New Drug Candidates
      • NDA/MAA-enabling Studies
      • Generic Drugs/Biosimilars
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • Phase I and ll Studies
      • Study Experience
      • In-hospital Beds
      • Cardiovascular Safety Services
      • Highly Automated ECG Core Lab
      • Metabolic Diseases
      • NAFLD/NASH
      • Belfast – Center of Excellence for Respiratory
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • AAHRPP Accreditation
      • Recruitment
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Clinical Data Sciences
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process – Internal Studies
      • Streamlined Data Flow Process – Multi-Site Studies
    • Global Bioanalytical Services
      • Assay Search
      • Small Molecule
      • Large Molecule
      • Biosimilars
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
    • Global Bioanalytical Services
  • Celerion Asia
  • Tobacco Risk Evaluation
    • Protocol Development and Data Interpretation
    • Global Clinical Research
    • Global Bioanalytical Services
    • Global Regulatory Services
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Studies
    • Data Management and Biometrics
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Customized Program Planning for Opening IND Study
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • Celerion Video Library
  • News & Events
    • Blog
    • Press Room
    • Conferences/Events
    • Clinical Discussion Forums
      • Past Clinical Discussion Forums
  • Participate in a Study
  • Careers
  • Celerion Science Newsletter 2018 Q2
  • Celerion Science Newsletter 2018 Q1
  • Celerion Science Newsletter 2017 Q4
  • Celerion Science Newsletter 2017 Q3
  • Celerion Science Newsletter 2017 Q2
  • Celerion Science Newsletter 2017 Q1
  • Celerion Science Newsletter 2016 Q3

Services > Data Management and Biometrics

Streamlined Data Flow Process - Internal Studies

Streamlined Data Flow Process Diagram – Internal Studies

Celerion’s streamlined data-flow process maintains consistency with industry-leading CDISC standards from data collection through data submission.

Data Capture
ClinQuick®, our proprietary electronic data-acquisition system, provides consistency of clinical operations across our sites, ensuring accurate, high-quality data and reducing time to database lock.

Data Output
Celerion utilizes in-house CDASH-compliant data-acquisition SAS® database format and associated electronic PDF format CRFs to set initial expectations, fully scope the project and standardize accepted data formats, resulting in time savings on the back-end. The submission database content/structure is usable throughout the drug-development lifecycle of a compound, reducing costs and eliminating rework.

Data Migration
Celerion expedites the conversion of clinical study data from CDASH to CDISC while maintaining compliance with FDA and other regulatory agencies. Our extensive services include biostatistics – detailed statistical analysis plans, and tables, figures and listings (TFLs) in addition to PK/PD analysis and interpretation.

Data Submission
Celerion is one of the leading CROs for complete data reporting, thereby saving sponsors’ time and money on overall drug-development timelines. The structure of the ICH E3 Clinical Study Report is compliant with the eCTD and is delivered as a fully electronic PDF format standard deliverable (vs. paper) to assist clients in their submission process.

See also...

Global Clinical Research: ClinQuick® Electronic Data Acquisition

Award Winning Scientific Poster: Adopted Changes for SDTMG V3.1.3 AND 2013 OpenCDISC Upgrades

Scientific Poster: Summing up - SDTM Trial Summary Domain

For more information contact us

  • LinkedIn
  • YouTube
  • Twitter

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2019 Celerion | Web Design by Aradius Group